Albiglutide

Albiglutide is a long-acting GLP-1 receptor agonist developed by GlaxoSmithKline (GSK) that consists of two copies of a modified GLP-1 sequence fused to human albumin. This albumin fusion design provides resistance to DPP-4 degradation and extends the plasma half-life to approximately 5 days, allowing once-weekly subcutaneous injection. The GLP-1 component contains a glycine-to-alanine substitution at position 8 that prevents DPP-4 cleavage.

Approved by the FDA in 2014 and marketed as Tanzeum (US) and Eperzan (EU), albiglutide was the fourth GLP-1 receptor agonist to reach the market. Clinical trials in the HARMONY program demonstrated HbA1c reductions of 0.6-0.9% and modest weight loss. However, albiglutide's glycemic efficacy and weight loss were generally less than those observed with liraglutide and dulaglutide in head-to-head comparisons, and the reconstitution process required by its lyophilized formulation was considered less convenient than competitors' ready-to-use pens.

Despite its commercial challenges, albiglutide made a significant scientific contribution through the HARMONY Outcomes cardiovascular trial, which demonstrated a 22% reduction in major adverse cardiovascular events compared to placebo in type 2 diabetes patients with established cardiovascular disease. This made albiglutide the third GLP-1 receptor agonist (after liraglutide and semaglutide) to demonstrate cardiovascular superiority.

GSK voluntarily withdrew albiglutide from the market in 2018, citing commercial considerations rather than safety or efficacy concerns. The drug's less competitive glycemic and weight loss profile, more complex administration, and intense competition in the GLP-1 receptor agonist class made it commercially unviable. Nevertheless, the HARMONY Outcomes data remain an important contribution to the GLP-1 cardiovascular evidence base.